N1-methylnicotinamide Mediates Multi-Target Cognitive Deficit Relief via AMPK-Lysosome Axis Regulation.
INTRODUCTION/OBJECTIVE Alzheimer's Disease (AD) progresses via interconnected Aβ aggregation, tau hyperphosphorylation, neuroinflammation, and lysosomal failure, while current single-target drugs only relieve cognitive symptoms without halting pathogenesis. Gut microbiota-derived N1-methylnicotinamide (MNAM) is associa...